LGVN
Longeveron Inc.
There isn't enough reported data to score LGVN yet.
LGVN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
LGVN's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LGVN PE Valuation
LGVN has no meaningful PE right now: it lost money over the past year.
LGVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect LGVN's losses to shrink, with revenue growing.
LGVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$62.80 | +$35.42 |
| Q2 2024 | -$87.40 | +$7.82 |
| Q1 2024 | -$96.10 | -$0.88 |
| Q4 2023 | -$102.00 | -$11.78 |
| Q3 2023 | -$98.22 | -$7.93 |
| Q2 2023 | -$95.22 | -$4.93 |
| Q1 2023 | -$95.22 | -$5.93 |
LGVN lost $62.80 per share over the past year, a smaller loss than the year before.
LGVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $115K | -16% |
| Q2 2026 | $287K | -9.2% |
| Q1 2026 | $398K | +4.5% |
| Q4 2025 | $365K | -39% |
| Q3 2025 | $137K | -82% |
| Q2 2025 | $316K | -32% |
| Q1 2025 | $381K | -30% |
| Q4 2024 | $603K | +857% |
LGVN's revenue has slid since its 2020 peak: $115,000 last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6258% | -923 points |
| Q2 2026 | -2150% | -442 points |
| Q1 2026 | -1200% | +160 points |
| Q4 2025 | -1479% | -769 points |
| Q3 2025 | -5336% | -4734 points |
| Q2 2025 | -1708% | -960 points |
| Q1 2025 | -1360% | -614 points |
| Q4 2024 | -710% | +7925 points |
LGVN's operating margin was −6258% last quarter, down 922 points from the same quarter a year ago, near the bottom of its range since 2019.
LGVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | +$2.4M |
| Q2 2026 | -$5.8M | -$2M |
| Q1 2026 | -$4.4M | +$354K |
| Q4 2025 | -$5.3M | -$1.9M |
| Q3 2025 | -$5.1M | -$1.8M |
| Q2 2025 | -$3.8M | +$1M |
| Q1 2025 | -$4.7M | -$1.6M |
| Q4 2024 | -$3.4M | +$775K |
LGVN has burned cash in almost every quarter: −$18M over the past year, against −$17M the year before.
LGVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +159% | +400K shares |
| 1 year | +208% | +440K shares |
| 3 years | +243% | +461K shares |
LGVN has 650,988 diluted shares, up 208% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | $141,000 |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LGVN Net Leverage
LGVN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LGVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.1 | Neutral |
| Stochastic | 11.1 | Oversold |
LGVN's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
LGVN PE vs Healthcare Sector
LGVN has no meaningful PE right now: it lost money over the past year.
LGVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.16 | 38% above |
| 20 week MA | $4.85 | 39% below |
| 50 week MA | $6.35 | 53% below |
| 100 week MA | $9.53 | 69% below |
| 200 week MA | $83.3 | 96% below |
LGVN has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 96% below its 200-week average.
LGVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $741.0 | $1,370.0 | +85% |
| 2022 | $1,370.0 | $327.0 | -76% |
| 2023 | $327.0 | $136.0 | -58% |
| 2024 | $136.0 | $17.5 | -87% |
| 2025 | $17.5 | $5.32 | -70% |
| 2026 YTD | $5.32 | $2.97 | -44% |
LGVN has finished four years in a row lower, and it's down 44% so far in 2026.